No major medical guideline sets a specific age at which you should stop getting DEXA scans. The U.S. Preventive Services Task Force recommends screening for osteoporosis in women aged 65 and older and in younger postmenopausal women at elevated risk, but it does not name an upper cutoff. The decision to stop screening is less about reaching a birthday and more about whether the results would change what you or your doctor actually do, and that depends on your life expectancy, your baseline bone density, whether you’re already being treated, and how reliably the scan can measure your bones at your age.
What the Guidelines Actually Say
The USPSTF’s most recent recommendation reaffirms that women 65 and older should be screened with bone mineral density testing, typically via DEXA. For postmenopausal women younger than 65, screening is recommended when clinical risk factors suggest their fracture risk is comparable to that of a 65-year-old white woman. The task force found insufficient evidence to recommend for or against screening in men at any age, a gap that remains frustrating for clinicians who see plenty of older men with fragility fractures.1United States Preventive Services Task Force. Recommendation: Osteoporosis to Prevent Fractures: Screening
What the guidelines conspicuously avoid is an upper boundary. They don’t say “stop at 85” or “no benefit after 90.” This silence isn’t an oversight. It reflects the reality that fracture risk keeps climbing with age, and that no trial has demonstrated a point where screening becomes useless. Some experts have recommended starting bone density screening in men at age 70, but even that threshold rests on limited evidence.2PubMed Central. Bone Density Screening and Re-screening in Postmenopausal Women and Older Men
When Repeat Scans Add Little Value
For many people, the real question isn’t whether to ever get screened again, but how often to repeat a scan they’ve already had. The evidence here is clearer than you might expect: if your first DEXA showed normal bone density or only mild thinning, repeating the scan every two or three years does almost nothing to improve fracture prediction. Cohort studies evaluated by the USPSTF found that retesting at intervals of four to eight years didn’t improve the accuracy of fracture prediction compared to just using the original result. Women whose baseline T-score was normal took nearly 17 years, on average, before even 10 percent of them progressed to osteoporosis. Women who started with mildly low scores progressed faster, reaching a similar threshold in about five years.3United States Preventive Services Task Force. Recommendation: Osteoporosis to Prevent Fractures: Screening – Section: Practice Considerations
A separate analysis of repeat scanning confirmed that for postmenopausal women without osteoporosis, a repeat bone density measurement offered no advantage in predicting fracture risk.4PubMed Central. Skip that repeat DXA scan in these postmenopausal women Despite this, repeat scans remain common in practice even among low-risk women. A longitudinal study found that roughly 8 percent of low-risk women had a repeat DEXA within two years of their initial screening, rising to about 43 percent by five years. That’s a lot of scanning for a group unlikely to have progressed to osteoporosis.5PubMed Central. Incidence and Predictors of Repeat Bone Mineral Densitometry: A Longitudinal Cohort Study
The practical takeaway: if you had a normal DEXA at 65, you probably don’t need another one for a decade or more. If your score was borderline, a shorter interval of roughly five years is reasonable. The habit of getting scanned every two years “just because” isn’t supported by the data for most women with good baseline results.
The Very Elderly Are Where Screening Matters Most
There’s a common assumption that screening becomes pointless after a certain age because the person may not live long enough to benefit from treatment, or because “everyone that old has thin bones anyway.” The evidence pushes back on both counts. About 30 percent of major osteoporotic fractures and roughly 60 percent of hip fractures occur in women aged 80 and older. In that age group, about one in five women has a FRAX-predicted major fracture risk of 20 percent or higher. The number of women you’d need to screen to find one at that high-risk threshold drops dramatically with age: roughly 30 younger women (aged 60 to 69) versus just two women aged 80 and older.6PubMed Central. Bone Mineral Density Measurements and Fracture Prediction in the Very Elderly
Screening in the very elderly is also cost-effective. An economic analysis of different screening strategies in postmenopausal women found that screening remained effective and cost-effective at age 80, and that the quality-adjusted life-days gained from screening tended to increase with age.7PubMed Central. Cost-Effectiveness of Different Screening Strategies for Osteoporosis in Postmenopausal Women This makes sense once you think it through: when fracture risk is high and the scan is cheap, the payoff from identifying someone who needs treatment is large.
Life Expectancy and Time to Benefit
The strongest reason to stop screening is when someone’s remaining life expectancy is too short for treatment to help. Bisphosphonates, the most widely prescribed class of osteoporosis medications, need time to work. A meta-analysis of randomized trials in postmenopausal women with osteoporosis calculated that you’d need to treat 100 women for about 12 months to prevent one nonvertebral fracture. Since most postmenopausal women have a life expectancy well beyond a year, bisphosphonate therapy is likely beneficial for the vast majority. The finding suggests that treatment is appropriate for anyone expected to live longer than roughly a year.8JAMA Internal Medicine. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials
Life expectancy data from a large observational cohort gives some context. A 75-year-old woman being treated for osteoporosis had an estimated remaining life expectancy of about 13.5 years, and a 75-year-old man about 7.5 years.9PubMed. Life Expectancy in Patients Treated for Osteoporosis: Observational Cohort Study Using National Danish Prescription Data For most people, even at advanced ages, that’s more than enough time for treatment to pay off. The relevant question is not “are you too old?” but “do you have enough time left for the medication to reduce your fracture risk before something else becomes more pressing?”
When life expectancy drops to a matter of months, screening and new treatment make little sense. This is a judgment call that depends on the person’s overall health, their other medical conditions, and their goals of care. There’s no formula that spits out the right answer, but the 12-month time-to-benefit figure is a useful benchmark in conversations between patients and clinicians.
Technical Problems With DEXA in Older Adults
Even when screening is clinically appropriate, the DEXA scan itself becomes less reliable as you age. The lumbar spine, one of the two standard measurement sites, accumulates degenerative changes over time: arthritis, disc narrowing, bone spurs, and aortic calcifications can all artificially inflate the bone density reading. A study comparing DEXA accuracy across age groups found that degenerative or artifact-related errors occurred in about 16 percent of lumbar spine scans in older adults, versus under 3 percent in younger people.10Journal of Clinical Densitometry. Pitfalls and sources of error in DXA reporting and interpretation: The role of age-associated comorbidities, structural changes, and artifacts — A descriptive focus on older adults
What this means in practice: a spine DEXA in an 85-year-old may read as “normal” when the actual bone is quite thin, because arthritis is stiffening and calcifying the area. Good technicians and interpreting physicians know to look at the hip instead when the spine is unreliable, but these artifacts still muddy the picture. If your doctor tells you your spine bone density is “fine” at an advanced age, it’s worth asking whether the spine site was trustworthy or whether the hip measurement tells a different story.
One emerging tool that partially sidesteps this problem is the trabecular bone score, a texture measure derived from the same spine DEXA image. Unlike the standard bone density number, TBS is relatively unaffected by the degenerative artifacts that plague spine readings in older adults.11Journal of Clinical Densitometry. Trabecular Bone Score Vertebral Exclusions Affect Risk Classification and Treatment Recommendations: The Manitoba Bmd Registry TBS assesses bone microarchitecture independently of density and can shift treatment recommendations, so it’s a useful add-on when a standard spine reading looks suspicious.
When You Can Skip the Scan Entirely
In some situations, you can estimate fracture risk without a DEXA at all. The FRAX tool, widely used by clinicians, calculates your ten-year probability of a major osteoporotic fracture and a hip fracture based on clinical risk factors like age, sex, weight, smoking status, alcohol use, glucocorticoid exposure, and prior fracture. FRAX can be run with or without a bone density number.
A study comparing FRAX scores calculated with and without BMD found that the two versions produced identical treatment recommendations for 84 percent of patients. Only about 1.3 percent of people who wouldn’t have been flagged for treatment by FRAX alone were reclassified as needing treatment once BMD was added.12PubMed Central. FRAX Prediction Without BMD for Assessment of Osteoporotic Fracture Risk For the oldest patients or those for whom getting to a DEXA machine is burdensome, a FRAX calculation using just clinical risk factors can be a reasonable substitute. This is especially relevant for people in nursing homes or with significant mobility limitations.
Quantitative ultrasound of the heel is another alternative that has shown promise for predicting fracture risk with quality approaching that of DEXA. These devices are portable, don’t involve radiation, and cost less than a DEXA scan, making them practical for use in settings where DEXA machines aren’t available.13PubMed Central. Quantitative Ultrasound and Bone Health in Elderly People, a Systematic Review For a homebound older adult or someone in a rural area far from a radiology center, heel ultrasound could inform the decision about treatment without requiring a trip to a DEXA facility.
Special Populations That Change the Calculus
Certain groups deserve ongoing monitoring regardless of age, because their risk of rapid bone loss is driven by something beyond normal aging. People taking glucocorticoids (like prednisone) for chronic conditions are a prime example. Guidelines recommend bone density testing every one to three years during glucocorticoid therapy, because steroid-induced bone loss is fast and can be severe even in people who started with good bone density.14PubMed Central. Understanding and Managing Corticosteroid-Induced Osteoporosis Stopping DEXA screening in someone on long-term steroids would mean flying blind in a situation where bone loss can outpace anything the person or doctor would predict from age alone.
Other high-risk groups include people on aromatase inhibitors for breast cancer, those with hyperparathyroidism, and anyone with a history of organ transplant and immunosuppressive therapy. For all of these, the question isn’t “when do I stop screening?” but “am I being screened often enough?”
Dementia, Nursing Homes, and Goals of Care
The hardest conversations about stopping DEXA screening happen in nursing homes and among people with advanced dementia. These individuals are at extremely high risk for fractures due to falls, immobility, and low bone density, but they are also less likely to tolerate or benefit from the medications that screening would trigger. A review of fracture prevention in nursing home residents with dementia found that the low use of osteoporosis medications in this group may reflect a deliberate attempt by prescribers to align medication use with changing goals of care, or it may represent genuine undertreatment in people who still have meaningful fracture risk.15Journal of the American Medical Directors Association. Controversies in Care Are Nursing Home Residents With Dementia Appropriately Treated for Fracture Prevention?
There is no simple answer here. A hip fracture in someone with severe dementia is a catastrophic event with high mortality, so preventing one matters. But if the person can’t swallow pills, can’t stay upright for 30 minutes after a bisphosphonate, and wouldn’t consent to or tolerate intravenous treatment, then the scan result wouldn’t change management. Screening is only useful when it can lead to an action you’re willing and able to take. When the answer to “what would we do differently?” is “nothing,” then the screening has become medical theater rather than medicine.
Falls Matter as Much as Bones
One reason clinicians sometimes over-rely on DEXA is that it produces a concrete number in a field full of uncertainty. But bone density is only one ingredient in fracture risk, and arguably not the most important one in the oldest patients. Falls are the proximate cause of most fractures in older adults, and fall risk is driven by muscle weakness, balance problems, medication side effects, poor vision, and environmental hazards.
A study of osteosarcopenia, the combination of low bone mass and low muscle mass, found that men with both conditions had roughly twice the odds of falls and about 2.6 times the odds of fractures compared to men without either condition.16ScienceDirect. Associations between Osteosarcopenia and Falls, Fractures, and Frailty in Older Adults: Results From the Canadian Longitudinal Study on Aging (CLSA) Muscle mass and strength are not captured by a DEXA scan in its standard bone-density mode (though body composition scans exist). At some point, the most effective fracture prevention strategy shifts from monitoring bone density to preventing falls: strength training, balance work, medication review, home safety modifications. A person in that situation may get more benefit from a physical therapy referral than from another DEXA scan.
Monitoring Treatment Is Different From Screening
An important distinction that sometimes gets lost: using DEXA to monitor someone already on osteoporosis treatment is a different question from using it to screen for new disease. If you’ve been diagnosed and started on medication, periodic DEXA scans can tell your doctor whether the treatment is working. A retrospective study found that monitoring with DEXA showed significant improvement in femoral neck bone density among patients taking alendronate with vitamin D, compared to other medication regimens.17PubMed Central. The Use of Bone Density Scan in Monitoring Treatment Response in Patients Diagnosed with Osteoporosis: A Retrospective Cohort Study
Stopping treatment monitoring scans follows a different logic than stopping screening scans. If you’re on a bisphosphonate drug holiday after several years of therapy, periodic DEXA can help decide when to restart. If you’ve switched medications because of side effects, a follow-up scan can confirm the new drug is working. These are clinical uses that remain appropriate regardless of age, as long as the treatment plan itself still makes sense.
Racial and Socioeconomic Disparities in Screening
Before worrying about overscreening, it’s worth acknowledging that many people are never adequately screened in the first place. Black women were about half as likely as white women to receive bone density testing before a hip fracture, and Hispanic women were about two-thirds as likely. Those disparities persisted even after a fracture: Black and Hispanic women remained significantly less likely to be tested after breaking a hip.18PubMed Central. Racial and socioeconomic disparities in bone density testing before and after hip fracture
This matters for the “when to stop” conversation because the question assumes screening has been happening. For many women of color and women with lower incomes, the more urgent issue is that screening never started or was never repeated at appropriate intervals. Clinicians focused on reducing unnecessary testing need to make sure they aren’t inadvertently widening disparities by applying “stop screening” guidance most aggressively to populations that were under-screened to begin with.
A Practical Framework for the Decision
Since no guideline draws a hard line, here’s how the considerations stack up in practice. Continuing DEXA screening generally makes sense when you meet several of these conditions: you have not yet been diagnosed with osteoporosis, your life expectancy exceeds a year or two, you would be willing to start or modify treatment based on the results, and you don’t already have enough clinical risk factors to justify treatment without a scan. Stopping or deferring scans is reasonable when your baseline scan was normal and was done within the last decade, or when you’re already on treatment and the scan is being ordered as routine repetition rather than to answer a specific clinical question, or when a FRAX calculation using clinical factors alone already provides enough information to guide treatment.
For the oldest adults, the decision pivots on whether the result would change management. An 88-year-old woman who is mobile, active, and willing to take medication probably benefits from knowing her bone density. An 88-year-old woman in hospice care does not. The scan itself is harmless and inexpensive, so the real cost of unnecessary screening isn’t the scan but the cascade of interventions, follow-ups, and medication side effects that flow from a result no one was prepared to act on. The right time to stop DEXA screening is when the answer it gives has stopped mattering.